Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $47.57.
The New Indian Express on MSN13h
BRS top brass’ silence on MLC polls baffles leaders in TelanganaHYDERABAD: The BRS appears to be not all that keen on contesting the ensuing graduates and teachers MLC elections likely to be held in March next year.The party ...
Sydney Sixers who were cruising well with close wins over Melbourne Stars and Hobart Hurricanes, lost their momentum as they ...
South Africa and India have all geared up for the series' crucial game as both teams take on each other in the 3rd T20I at ...
Swiggy has released a heartwarming ad film (conceptualized in-house) that encapsulates the brand’s ethos and the decade-long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback